Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of PGC: rating 4
(4 out of 5)



Link Market Services Melbourne
Tower 4, 727 Collins Street Docklands VIC 3008
Tel : +61 3 9615 9800 or 61 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PGC4
Address: Level 4, 96-100 Albert Road South Melbourne, VIC 3205
Tel:  1300 369 559Fax: 03 8833 7890

Date first listed: 15/10/1999

Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Providers of integrated services to Australia's health and aged care markets

News & Events

Expand this box to read and print

The suspension of trading in the securities of Paragon Care Limited will be lifted immediately following the release by PGC of its Appendix 4D and half year accounts for the period ended 31 December 2023 and an announcement regarding the application of Listing Rules 11.1.2 and 11.1.3 to the acquisition of CH2 Holdings Pty Ltd by PGC.


The company releases its PGC-CH2 Merger Presentation.


ParagonCare notified ASX of the Merger in accordance with Listing Rule 11.1 and sought in-principle advice regarding the application of Listing Rules 11.1.2 and 11.1.3. ASX has confirmed that: ParagonCare is not required to seek shareholder approval under Listing Rule 11.1.2; and ParagonCare is not required to meet the requirements in Chapters 1 and 2 of the Listing Rules as if ParagonCare were applying for admission to the official list under Listing Rule 11.1.3. The Board unanimously recommends that ParagonCare shareholders vote in favour of the resolutions to be considered at the general meeting in respect of the Merger, in the absence of a superior proposal and subject to an independent expert concluding that the Merger is fair and reasonable to ParagonCare shareholders.


S&P Dow Jones Indices Announces March 2024 Quarterly Rebalance of the S&P/ASX Indices. ParagonCare was removed from the list of All Ordinaries "“ Effective Prior to the Open on March 18, 2024.


The company releases a notice of proposed issue of securities.


ParagonCare is pleased to announce the proposed merger with CH2, establishing a premier healthcare wholesaler, distributor, and manufacturer. The Merger enables ParagonCare to facilitate expansion into both existing companies' healthcare wholesaling and distribution networks across Australia, and New Zealand and Asia. This transformative merger signals a strategic move to capitalise on and strengthen our combined operational capabilities in rapidly growing markets. Merger highlights: Combined estimated FY24 pro-forma1 revenues of $3.3 billion and EBITDA of $93 million; Broad geographic reach with direct operations in 8 countries across Australia, New Zealand and Asia Pacific region; Significant synergies identified across the business platform; Experienced management team and Board capitalising on growth in these dynamic growing markets; Extensive first-tier partner/supplier network; Cross-selling opportunities across both businesses; Creates a robust framework for both organic and acquisitive growth; Best-in-class logistics, technology and innovation healthcare solution provider; Fully integrated and truly independent supplier; Potential for significant shareholder value creation.


The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Friday, 1 March 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 29 February 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.


we understand that on or about this date the company consolidated its shares 1 for 10


ASIC has succeeded in obtaining a pecuniary penalty order and disqualification order in civil penalty proceedings against Mr Ravi Amrit Narain of Bellarine, Victoria. Mr Narain was a former managing director and chief executive officer of Citrofresh International Limited, now known as Paragon Care Limited


name changed from Citrofresh International Limited



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    28/06/2023Mark Hooper914,347$0.220$201,156
    20/10/2022Brent Stewart149,500$0.330$49,335
    20/10/2022Mark Hooper1,000,000$0.325$325,000
    20/10/2022Geoffrey Sam300,000$0.325$97,500
    07/10/2022Shane Tanner30,274$0.360$10,899

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Peter LacazeChairman03/06/2024
    David CollinsManaging Director, CEO03/06/2024
    Michael PetersCFO21/03/2024
    Alan McCarthyIndependent Director16/02/2022
    Carmen RileyDirector03/06/2024
    Melanie LeydinCompany Secretary
    Claire Newstead-SinclairCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Shane TannerNon Exec Chairman21/12/200503/06/2024
    John WalstabManaging Director, CEO16/02/202203/06/2024
    Geoffrey SamIndependent Director03/06/201603/06/2024
    Brent StewartNon Exec Director31/05/201803/06/2024
    Josephine De MartinoCFO03/10/202220/03/2024
    Mark HooperManaging Director, CEO05/04/202218/09/2023
    Stephen MundayCFO01/06/201531/12/2022
    Mark SimariNon Exec Director13/02/200730/11/2022
    Phil NichollCEO02/12/201905/04/2022
    Paul LiNon Exec Director27/01/202102/09/2021
    Bruce BianIndependent Director13/03/201920/08/2020
    Michael NewtonNon Exec Director22/06/200730/06/2020
    Andrew JustManaging Director, CEO22/01/201827/11/2019
    Brett CheongNon Exec Director02/07/200931/05/2018
    Michael G. RiceAlternate Director31/05/2018
    Matt ParkerCFO01/04/201413/03/2015
    Darryl LevinCFO06/10/200913/02/2013
    Tim BlancheExecutive Director02/07/200903/07/2012

    Date of first appointment, title may have changed.